KRAS and neuroblastoma: SGSS05-NS3 at 3.2 μM exhibited average IC50 at 96 h and a highly significant p-value for the In Vitro Therapeutic Index (IVTI) across the 8 NB cell lines compared with control cell lines (Figure S1A-S1C and Table S1).